Chronic Pain
Conditions
Brief summary
This project is a pilot study to evaluate the analgesic and opioid-sparing effects of ketamine in an ultra-low dose oral formulation as a novel intervention for treatment of chronic non-cancer pain in opioid-tolerant patients in the primary care outpatient setting.
Detailed description
Chronic pain is a major national public health issue, affecting about 100 million adults in the United States. Opioid pain medications are commonly used for treatment of chronic pain, but their use is fraught with consequences including an increasing prevalence of misuse, abuse, and overdose death, and side effects which lead to a reduced quality of life. An effective and safe medication that would improve control of chronic pain while reducing reliance on opioid medications would be valuable for patients, medical providers and society at large. Ketamine, commonly used as an intravenous anesthetic agent, has been shown to have analgesic and opioid-sparing effects in the peri-operative period and in the palliative care setting. Based on promising preliminary data from an open-label treatment trial, this project is a pilot study to evaluate the analgesic and opioid-sparing effects of ketamine in an ultra-low dose oral formulation as a novel intervention for treatment of chronic non-cancer pain in the primary care outpatient setting. The design of the proposed study is a randomized controlled two week parallel-group trial, with 32 patients receiving either the active treatment or placebo twice daily.
Interventions
DRUGKetamine
ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
Sponsors
University of Washington
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 years or older * Routine use of an opioid medication for non-cancer pain for more than six months * A current average daily dose of greater than or equal to 20 mg morphine or equivalent * Current prescription of an as-needed opioid suitable for downward titration during the study period * Ability to provide informed consent Ability to adhere to the study protocol
Exclusion criteria
* Uncontrolled hypertension, cardiac arrhythmia or other known cardiac disease, * elevated intracranial pressure, * severe glaucoma, * schizophrenia, * diagnosed substance use disorder, or * other unstable medical or psychiatric illness or pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain improvement (Brief Pain Inventory (BPI) Mean Pain Severity Scale) | 2 weeks | Improvement after 2 weeks in pain as measured by the Brief Pain Inventory (BPI) Mean Pain Severity Scale |
| Function improvement (BPI Mean Interference Scale) | 2 weeks | Improvement after 2 weeks in functional status as measured by the BPI Mean Interference Scale |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in opioid use (self-reported average opioid dose) | 2 weeks | Reduction after two weeks in self-reported average opioid dose, converted to morphine equivalents. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Reduction in depression (PHQ-9 depression score) | 2 weeks | Reduction in depression, using the PHQ-9 depression score |
Countries
United States
Outcome results
None listed